血浆miR-136-5p表达水平对口腔鳞状细胞癌患者预后预测的价值

doi:10.19438/j.cjoms.2020.06.011

摘要/Abstract

摘要： 目的: 探讨血浆miR-136-5p表达水平对口腔鳞状细胞癌(OSCC)患者预后预测的价值。方法: 选择2015年1月—2018年10月儋州市人民医院收治的OSCC患者86例及正常对照组50例,采用实时荧光定量PCR技术检测2组患者血浆miR-136-5p表达水平。通过ROC曲线确定血浆miR-136-5p表达水平的最佳截断值,并以此为标准,将OSCC患者分为高miR-136-5p组(n=36)和低miR-136-5p组(n=50),对2组临床病理特征进行比较。应用Kaplan-Meier法绘制生存曲线,采用SPSS 20.0软件包中的单因素及多因素Cox回归模型,分析影响OSCC患者预后不良的危险因素。结果: OSCC组患者血浆miR-136-5p表达水平(1.27±0.51)显著低于对照组(4.38±1.26,P<0.01);血浆miR-136-5p低表达与OSCC患者的临床分期、分化程度、肿瘤直径及颈淋巴结转移有关(P<0.05)。生存分析显示,低miR-136-5p组患者总生存率(48.0%)显著低于高miR-136-5p组(68.4%,P<0.01),低miR-136-5p组患者无进展生存率(28.6%)显著低于高miR-136-5p组患者(57.8%,P<0.01)。多因素Cox回归模型分析显示,临床分期[HR(95%CI)=2.462(1.805~4.193)]、颈淋巴结转移[HR(95%CI)=2.913(2.142~5.827)]及血浆miR-136-5p表达水平<2.82[HR(95%CI)=3.856(3.114~8.205)]是影响OSCC患者预后不良的独立危险因素(P<0.05)。结论: 血浆miR-136-5p低表达与OSCC患者生存期短有关,有望作为预测OSCC预后不良的生物标志物。

关键词: 口腔鳞状细胞癌, miR-136-5p, 预后预测

Abstract: PURPOSE: To investigate the prognostic value of plasma level of miR-136-5p in patients with oral squamous cell carcinoma (OSCC). METHODS: From January 2015 to October 2018, 86 OSCC patients and 50 normal controls were selected from Danzhou People's Hospital. The expression of miR-136-5p in plasma of the two groups were detected by real-time fluorescence quantitative PCR. The optimal cut-off value of plasma miR-136-5p expression level was determined by ROC curve, and OSCC patients were divided into high miR-136-5p group(n=36) and low miR-136-5p group (n=50). The clinicopathological features of the two groups were compared. Survival curves were drawn by Kaplan-Meier method. Single factor and multi factor Cox regression models in SPSS 20.0 software package were used to analyze the risk factors of poor prognosis in OSCC patients. RESULTS: The expression level of plasma miR-136-5p in OSCC group(1.27±0.51) was significantly lower than that in the control group (4.38±1.26, P<0.01). Low expression of plasma miR-136-5p was related to the clinical stage, differentiation degree, tumor diameter and cervical neck lymph node metastasis of OSCC (P<0.05). Survival analysis showed that the overall survival rate of low miR-136-5p group(48.0%) was significantly lower than that of high miR-136-5p group (68.4%,P<0.01), and the progression-free survival rate of low miR-136-5p group(28.6%) was significantly lower than that of high miR-136-5p group (57.8%,P<0.01). Multivariate Cox regression model analysis showed that clinical stage [HR(95%CI) =2.462(1.805-4.193)], cervical neck lymph node metastasis [HR (95%CI)= 2.913 (2.142-5.827)and plasma miR-136-5p expression<2.82 [HR (95%CI)=3.856 (3.114-8.205)were independent risk factors for poor prognosis of patients with OSCC(P<0.05). CONCLUSIONS: Low expression of plasma miR-136-5p is related to short survival time of OSCC patients, which is expected to be a biomarker for predicting poor prognosis of OSCC.

Key words: Oral squamous cell carcinoma, miR-136-5p, Prognostic prediction

中图分类号:

R739.8

陈秀敏, 刘族志, 林建能. 血浆miR-136-5p表达水平对口腔鳞状细胞癌患者预后预测的价值[J]. 中国口腔颌面外科杂志, 2020, 18(6): 526-530.

CHEN Xiu-min, LIU Zu-zhi, LIN Jian-neng. Prognostic value of plasma level of miR-136-5p in patients with oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2020, 18(6): 526-530.

参考文献

[1] Saira, Ahmed R, Malik S, et al. Epidemiological and clinical correlates of oral squamous cell carcinoma in patients from north-west Pakistan[J]. J Pak Med Assoc, 2019, 69(8): 1074-1078.
[2] Chamorro Petronacci CM, Pérez-Sayáns M, Padín Iruegas ME, et al.miRNAs expression of oral squamous cell carcinoma patients: Validation of two putative biomarkers[J]. Medicine (Baltimore), 2019, 98(13): e14922.
[3] Chen Z, Tao Q, Qiao B, et al.Silencing of LINC01116 suppresses the development of oral squamous cell carcinoma by up-regulating microRNA-136 to inhibit FN1[J]. Cancer Manag Res, 2019, 11: 6043-6059.
[4] Ng JH, Iyer NG, Tan MH, et al.Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study[J]. Head Neck, 2017, 39(2): 297-304.
[5] Singh P, Srivastava AN, Sharma R, et al.Circulating microRNA-21 expression as a novel serum biomarker for oral sub-mucous fibrosis and oral squamous cell carcinoma[J]. Asian Pac J Cancer Prev, 2018, 19(4): 1053-1057.
[6] Cao M, Zheng L, Liu J, et al.MicroRNAs as effective surrogate biomarkers for early diagnosis of oral cancer[J]. Clin Oral Investig, 2018, 22(2): 571-581.
[7] Schneider A, Victoria B, Lopez YN, et al.Tissue and serum microRNA profile of oral squamous cell carcinoma patients[J]. Sci Rep, 2018, 8(1): 675.
[8] Xie ZC, Li TT, Gan BL, et al.Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis[J]. Pathol Res Pract, 2018, 214(5): 644-654.
[9] Paszek S, Gablo N, Barnas E, et al.Dysregulation of microRNAs in triple-negative breast cancer[J]. Ginekol Pol, 2017, 88(10): 530-536.
[10] Chen L, Hu J, Pan L, et al.Diagnostic and prognostic value of serum miR-99a expression in oral squamous cell carcinoma[J]. Cancer Biomark, 2018, 23(3): 333-339.
[11] Sun L, Liu L, Fu H, et al.Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients[J]. Med Sci Monit, 2016, 22: 289-294.
[12] Dumache R.Early diagnosis of oral squamous cell carcinoma by salivary microRNAs[J]. Clin Lab, 2017, 63(11): 1771-1776.
[13] Shi J, Bao X, Liu Z, et al.Serum miR-626 and miR-5100 are promising prognosis predictors for oral squamous cell carcinoma[J]. Theranostics, 2019, 9(4): 920-931.
[14] Troiano G, Mastrangelo F, Caponio VCA, et al.Predictive prognostic value of tissue-Based microRNA expression in oral squamous cell carcinoma: a systematic review and meta-analysis[J]. J Dent Res, 2018, 97(7): 759-766.
[15] Yan Y, Wang X, Venø MT, et al.Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients[J]. Oncotarget, 2017, 8(5): 8206-8214.